Using PSMA PET-CT as a Diagnostic Tool for Detection of Prostatic Cancer at an Early Stage
Launched by SHEBA MEDICAL CENTER · Oct 2, 2019
Trial Information
Current as of April 26, 2025
Unknown status
Keywords
ClinConnect Summary
The aim of the study is the evaluation of the possible role of PSMA PET-CT in early detection of prostate cancer, reducing rate of unnecessary prostate biopsies, and in cases of prostate cancer, correct staging of the disease and corresponding management.
Consequently, use of PSMA PET-CT in patients with suspicious PSA changes may improve our knowledge whether the prostate tumor is clinically significant or not (for the development of PSMA PET-CT with 68 Ga ligand allows to visualize prostate cancer with aggressive patterns), and improve clinical decision making for performing prostate bio...
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • 1. Men aged 40-75
- • 2. With or without suspicious DRE,
- • 3. Were referred by their treating physicians for prostate cancer biopsy based on either an elevated PSA result, a suspicious DRE exam, or both
- • 4. 4 \< PSA ≤ 10 ng/ml
- • -
- Exclusion Criteria:
- • 5. A previous diagnosis of prostate cancer
- • 6. Underwent previous prostate biopsy
- • 7. Previous radiation to pelvis for any reason
- • -
About Sheba Medical Center
Sheba Medical Center, located in Israel, is a leading academic medical institution renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent clinical trial sponsor, Sheba Medical Center leverages its multidisciplinary expertise and state-of-the-art facilities to conduct rigorous clinical studies aimed at improving patient outcomes and developing novel therapeutic interventions. The center's collaborative environment fosters partnerships with global research organizations, enhancing its ability to contribute to the scientific community and drive medical advancements across various fields. With a strong focus on patient safety and ethical standards, Sheba Medical Center is dedicated to translating research findings into practical applications that benefit patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ramat Gan, , Israel
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials